NeOnc Technologies, Inc. (NTI) is a Phase 2 cancer biotechnology company focused on intranasal (delivery through the nose) inhalation of a highly purified form of monoterpenes (oils from fruits & plants), alone or with other chemotherapeutics (cancer treatment chemicals) agents. The ongoing clinical trial of NEO100 (the company's first compound) treating malignant brain cancer (gliomas) is proving this delivery platform's effectiveness in passing the Blood-Brain Barrier. The results of Phase one are very encouraging and Phase 2 will begin in 30 days. NeOnc has strong patent protection for this platform and many other indications.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):